There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Two-thirds of Americans report spring allergies, and about 4 in 10 say they take an allergy medication several times a week. But those medicines, while valuable, don’t exactly fix the problem. One ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

(dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. In addition to COPD, Dupixent is approved in ...

Objectives: We reviewed asthma coexistence and the selection of biologic therapies in CRSwNP Management. Methods: The literature review utilized Google and Google Scholar, in addition to PubMed, EBSCO ...

asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, CSU and COPD in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...

asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, CSU and COPD in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is ...